From the News
Echoes of some news flashes from our collaborators:
Below we summarize press-releases in relation to Tribodies.
Tribodies are multispecific antibody derivatives, with robust and easy development possibilities. Tribodies consist of a fusion of 2 binding elements (such as scFv, or VHH) to a Fab. Tribodies have been shown superior activity as bispecific T-cell engagers, multiparatopic receptor internalization, and multispecific checkpoint inhibitors in immuno-oncology.
Tribodies were created at VIB*, and transferred first to Biotecnol, which later sold technology and a lead product to Chiome Bioscience (CBA-1535 / TB535).
*Schoonjans, R., Willems, A., Schoonooghe, S., Fiers, W., Grooten, J., Mertens, N., 2000. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J Immunol 165, 7050–7.
First patient injected With cancer therapeutic Tribody CBA-1535 in a Phase I clinical trial
Chiome Bioscience Inc. announced that the first patient has been dosed with CBA-1535 in a Phase I clinical trial.
The first part of the trial will evaluate the safety tolerability, pharmacokinetics, and identification of biomarker for the solid tumor patients . In the expansion part, exploratory efficacy will be evaluated in combination with cancer immunotherapy agent Pembrolizuma.
This first in human study is conducted at National Cancer Center Hospital and Shizuoka Cancer Center (Japan).
Release of Research Publication using Tribody™ Technology onto Cancer Immunotherapy from Chiome Bioscience (JP) in collaboration with CEINGE (IT)
Tribodies combining blockers for PD-1, PD-L1 and LAG-3 showed enhanced activity on activating lymphocytes as compared to a mix of the parental mAbs, with lower toxicity on normal tissue.
Chiome Bioscience Inc. announced submittion for a Phase I study on CBA-1535 (TB535)
Chiome Bioscience Inc., announced that it has submitted an initial application for a Phase I study on CBA-1535 to the Pharmaceuticals and Medical Devices Agency (PMDA, Japan) on February 16, 2022.
Biotecnol and Chiome Bioscience have entered into an asset purchase agreement.
Under this agreement, Biotecnol divested from it’s immuno-oncology pipeline and respective technologies (including Tb535H, and Trisoma®. Chiome will continue research and clinical development for Tb535H. In addition, Chiome will continue generating new immune-oncology products using Biotecnol’s Trisoma® technology. Financial details were not disclosed
SureTAC
Development Updates
Below we summarize press-releases in relation to SureTACs.
SureTACs are multispecific antibody derivatives designed to obtain targeted protein degradation, and thereby regulating pathological overexpression of certain membrane receptors.
Oncode Investigator Madelon Maurice receives KWF funding for innovative SureTAC technology
KWF has announced that Laigo Bio, a public-private collaboration between Oncode Bridge Fund and Argobio, will receive 1.2 million euros subsidy.
Oncode Institute and ArgoBio launch Laigo Bio
Laigo Bio is a targeted protein degradation biotech with programs in oncology and neurological disorders
Svenska Vaccinfabriken (SVF) granted US-patent regarding chimeric genes for immunotherapy against chronic hepatitis B and D virus infections
The 2nd of February 2021, SVF was granted a U.S patent (No: 10,905,760) covering chimeric genes and polypeptides that are useful for the generation, enhancement, or improvement of the immune response to chronic hepatitis B and D virus infections.